Oxford BioMedica saw the highest growth of 149% in patent filings in December and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 66% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Oxford BioMedica’s patent filings and grants. Buy the databook here.
Oxford BioMedica has been focused on protecting inventions in Australia(AU) with one publication in Q4 2023
The Australia(AU) Patent Office dominates the patent filings and grants with nearly . The Australia(AU) patent Office are among the top ten patent offices where Oxford BioMedica is filings its patents. Among the top granted patent authorities, Oxford BioMedica has 100% of its grants in Australia(AU)
Johnson & Johnson could be the strongest competitor for Oxford BioMedica
Patents related to genomics and nanomedicine lead Oxford BioMedica's portfolio
Oxford BioMedica has the highest number of patents in genomics followed by, nanomedicine. For genomics, nearly 67% of patents were filed and no patents were granted in Q4 2023.
Human immunodeficiency virus (hiv) infections (aids) related patents lead Oxford BioMedica portfolio
Oxford BioMedica has highest number of patents in human immunodeficiency virus (hiv) infections (aids).
For comprehensive analysis of Oxford BioMedica's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.